Evidence map›Paper›PMID 20023047›Full record

Trial reportEuropean journal of heart failure2010

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.

Paula K Lorgelly, Andrew H Briggs, Hans Wedel, Peter Dunselman, Ake Hjalmarson, John Kjekshus, Finn Waagstein, John Wikstrand, András Jánosi, Dirk J van Veldhuisen and 4 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04895059 (Study of no Pharmacokinetic Interaction Between Rosuvastatin 20 mg and Ezetimibe 10 mg, Open Design, Randomized, Single Dose, 3x6, Crossove, Healthy Volunteers in Fasting, in Fixed Combination Against Individuals Components Managed), which is not on this map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04895059 phase1completednot on this mapstarted 2017, after this paper: background citation

Study of no Pharmacokinetic Interaction Between Rosuvastatin 20 mg and Ezetimibe 10 mg, Open Design, Randomized, Single Dose, 3x6, Crossove, Healthy Volunteers in Fasting, in Fixed Combination Against Individuals Components Managed

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2017 to 2018Enrolled36ConditionsHealthyArmsRosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose, Rosuvastatin 20mg, Ezetimibe 10mg
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Cholesterol-lowering drugs: science and marketing.Journal of the Royal Society of Medicine · 2017
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 7 countries.

Paula K LorgellySection of Public Health and Health Policy, Faculty of Medicine, University of Glasgow, Glasgow G12 8RZ, UK.
Andrew H Briggs
Hans Wedel
Peter Dunselman
Ake Hjalmarson
John Kjekshus
Finn Waagstein
John Wikstrand
András Jánosi
Dirk J van Veldhuisen
Vivencio Barrios
Cândida Fonseca
John J V McMurray
CORONA Study Group
University of Gothenburg · SEPublic Health Scotland · GBAmphia Ziekenhuis · NLBritish Heart Foundation · GBHospital Universitario Ramón y Cajal · ESNordic School of Public Health · SEOslo University Hospital · NOSzent János Kórház · HUUniversity Medical Center Groningen · NLUniversity of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial. METHODS AND

resultsThis within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075-0.254, P < 0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin ( pound1531 vs. pound1769; difference pound238; 95% CI: pound73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group ( pound1769 vs. pound2072; difference pound303; 95% CI: pound138-468, P < 0.001). Overall, rosuvastatin was found to cost pound1840 (95% CI: pound562-6028) per major CV event avoided.

conclusionThis economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.

Indexed as

AgedCardiopulmonary BypassCost-Benefit AnalysisCosts and Cost AnalysisFemaleFluorobenzenesHeart FailureHeart TransplantationHospitalizationHospital MortalityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedProspective StudiesPyrimidinesFluorobenzenesHydroxymethylglutaryl-CoA Reductase InhibitorsPyrimidinesRosuvastatin CalciumSulfonamides

Identifiers

PMID20023047
PMCPMC2796144
OpenAlexW2063035288

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.